Abstract 245P
Background
Cervical cancer ranked second on women in Indonesia with 23.4/100,000 population incidence and 13.9/100,000 population mortality, emphasizing the importance of its screening and prevention. Indonesian government have applied cancer “see and treat” method with visual inspection using acetic acid (VIA) followed by cryotherapy procedure, but the number of women complying with the program were only 5% despite 80% target in 2013. This study aimed to explore factors influencing women with VIA positive result’s likelihood to receive cryotherapy.
Methods
Our cross-sectional study observed “see and treat” program at Temanggung District Health Office, Central Java, Indonesia, between March 29 and April 31, 2018. We used simple random sampling technique to select 356 VIA possitive women aged 30-50 years and collected data on whether they underwent cryotherapy, their demographic profile, education, knowledge and awareness about cryotherapy, and family support using structured questionnaire. Data were analyzed with chi square analysis on STATA software.
Results
In our study, 217 women (60.69%) received cryotherapy, while 139 women (39.04%) did not. Among all variables analysed, factors affecting subjects’ likelihood to underwent cryotherapy are knowledge about cryotherapy itself (PR = 0.776, 95%CI=0.660-0.913, p = 0.003), residence distance (PR = 0.795, 95%CI=0.650-0.971, p = 0.016), permission from family (PR = 0.675, 95%CI=0.556-0.820, p = 0.018), and accompaniment by their family (PR = 0.824, 95%CI=0.700-0.970, p = 0.026). Age, marital status, occupation, and education background did not show significant correlation with women’s decision to receive cryotherapy.
Conclusions
Our study showed that more individuals with VIA positive results were willing to receive cryotherapy as an effort to prevent cervical cancer. However, our study also showed knowledge about cryotherapy, residence distance, family permission and family accompaniment as factors lowering VIA possitive women’s likelihood to receive cryotherapy. Because this study is only limited on Temanggung population, further study is needed to explore larger population and other factors that might also influence this behavior.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Funding
Board for Development and Empowerment Human Resources of Health, Ministry of Health Republic of Indonesia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract